Real-time Estimate
Cboe BZX
18:33:10 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
14.24
USD
|
+2.01%
|
|
+2.83%
|
-11.98%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,054
|
5,978
|
4,201
|
1,167
|
2,062
|
1,783
|
-
|
-
|
Enterprise Value (EV)
1 |
3,054
|
5,853
|
4,496
|
1,515
|
2,332
|
2,048
|
2,021
|
1,963
|
P/E ratio
|
366
x
|
1,346
x
|
-487
x
|
-7.97
x
|
-23.1
x
|
-24.9
x
|
-38.9
x
|
-53.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.47
x
|
13.5
x
|
8.67
x
|
2.29
x
|
3.49
x
|
2.72
x
|
2.48
x
|
2.25
x
|
EV / Revenue
|
7.47
x
|
13.2
x
|
9.28
x
|
2.97
x
|
3.94
x
|
3.12
x
|
2.81
x
|
2.48
x
|
EV / EBITDA
|
53.4
x
|
168
x
|
-1,080
x
|
-31.6
x
|
669
x
|
88.5
x
|
41.7
x
|
25.3
x
|
EV / FCF
|
914,347,968
x
|
-211,772,255
x
|
-49,477,433
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5.79
x
|
8.69
x
|
3.82
x
|
1.18
x
|
2.19
x
|
1.97
x
|
2.01
x
|
1.96
x
|
Nbr of stocks (in thousands)
|
104,408
|
111,030
|
123,122
|
126,303
|
127,466
|
127,712
|
-
|
-
|
Reference price
2 |
29.25
|
53.84
|
34.12
|
9.240
|
16.18
|
13.96
|
13.96
|
13.96
|
Announcement Date
|
27/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
408.8
|
444.4
|
484.3
|
509.7
|
591.6
|
655.6
|
719
|
790.7
|
EBITDA
1 |
57.22
|
34.84
|
-4.161
|
-48.01
|
3.486
|
23.15
|
48.47
|
77.58
|
EBIT
1 |
13.01
|
-13.99
|
-118.8
|
-157.6
|
-107.7
|
-85.36
|
-62.48
|
-50.83
|
Operating Margin
|
3.18%
|
-3.15%
|
-24.52%
|
-30.92%
|
-18.21%
|
-13.02%
|
-8.69%
|
-6.43%
|
Earnings before Tax (EBT)
1 |
3.645
|
-14.06
|
-15.08
|
-159.3
|
-97.1
|
-75.77
|
-54.02
|
-42.95
|
Net income
1 |
8.006
|
4.172
|
-8.347
|
-144.2
|
-87.97
|
-70.12
|
-46.91
|
-35.56
|
Net margin
|
1.96%
|
0.94%
|
-1.72%
|
-28.3%
|
-14.87%
|
-10.69%
|
-6.52%
|
-4.5%
|
EPS
2 |
0.0800
|
0.0400
|
-0.0700
|
-1.160
|
-0.7000
|
-0.5600
|
-0.3588
|
-0.2625
|
Free Cash Flow
|
3.34
|
-27.64
|
-90.86
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
0.82%
|
-6.22%
|
-18.76%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
5.84%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
41.72%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
125.7
|
117.2
|
125.1
|
128.8
|
138.7
|
137.2
|
146.9
|
152
|
155.6
|
156.2
|
162.3
|
166.5
|
172.3
|
168.4
|
178.6
|
EBITDA
1 |
-9.785
|
-19.01
|
-16.27
|
-11.56
|
-1.168
|
-7.116
|
-2.051
|
3.305
|
9.348
|
3.492
|
3.992
|
5.867
|
11.28
|
5.49
|
12.07
|
EBIT
1 |
-41.57
|
-52.03
|
-39.7
|
-39.51
|
-26.38
|
-35.07
|
-29.89
|
-24.2
|
-18.57
|
-30.57
|
-21.67
|
-19.87
|
-14.61
|
-21.62
|
-15.79
|
Operating Margin
|
-33.06%
|
-44.4%
|
-31.74%
|
-30.68%
|
-19.02%
|
-25.56%
|
-20.35%
|
-15.92%
|
-11.94%
|
-19.56%
|
-13.35%
|
-11.93%
|
-8.47%
|
-12.84%
|
-8.84%
|
Earnings before Tax (EBT)
1 |
-44.2
|
-53.16
|
-41.03
|
-39.62
|
-25.52
|
-33.72
|
-26.64
|
-21.45
|
-15.29
|
-27.68
|
-19.2
|
-18.14
|
-12.25
|
-18.59
|
-12.92
|
Net income
1 |
-41.76
|
-49.41
|
-35.3
|
-36.85
|
-22.69
|
-30.8
|
-24.33
|
-18.52
|
-14.33
|
-27.06
|
-17.41
|
-16.29
|
-10.95
|
-16.57
|
-11.42
|
Net margin
|
-33.21%
|
-42.17%
|
-28.23%
|
-28.62%
|
-16.36%
|
-22.44%
|
-16.56%
|
-12.19%
|
-9.21%
|
-17.32%
|
-10.73%
|
-9.78%
|
-6.36%
|
-9.84%
|
-6.39%
|
EPS
2 |
-0.3400
|
-0.4000
|
-0.2800
|
-0.3000
|
-0.1800
|
-0.2500
|
-0.1900
|
-0.1500
|
-0.1100
|
-0.2100
|
-0.1362
|
-0.1262
|
-0.0875
|
-0.1283
|
-0.0883
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/02/22
|
27/04/22
|
09/08/22
|
08/11/22
|
23/02/23
|
08/05/23
|
08/08/23
|
06/11/23
|
20/02/24
|
30/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
295
|
348
|
269
|
265
|
238
|
180
|
Net Cash position
1 |
-
|
125
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-70.86
x
|
-7.242
x
|
77.22
x
|
11.46
x
|
4.909
x
|
2.32
x
|
Free Cash Flow
|
3.34
|
-27.6
|
-90.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
1.93%
|
0.69%
|
-3.63%
|
-6.63%
|
-1.53%
|
0.25%
|
1.75%
|
6.18%
|
ROA (Net income/ Total Assets)
|
1.32%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
607.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.050
|
6.190
|
8.930
|
7.860
|
7.390
|
7.080
|
6.950
|
7.140
|
Cash Flow per Share
2 |
0.2300
|
0.0100
|
-0.2200
|
-0.5300
|
-0.0200
|
0.3700
|
0.6900
|
-
|
Capex
1 |
20
|
29.1
|
64.1
|
30.9
|
28.8
|
24.7
|
25.1
|
-
|
Capex / Sales
|
4.9%
|
6.55%
|
13.24%
|
6.06%
|
4.86%
|
3.77%
|
3.49%
|
-
|
Announcement Date
|
27/02/20
|
24/02/21
|
23/02/22
|
23/02/23
|
20/02/24
|
-
|
-
|
-
|
Last Close Price
13.96
USD Average target price
20.1
USD Spread / Average Target +43.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.98% | 1.78B | | -19.14% | 8.22B | | +46.91% | 3.73B | | -8.06% | 2.46B | | -38.71% | 2.46B | | -8.84% | 2.36B | | -18.57% | 1.52B | | -40.78% | 1.21B | | +8.32% | 1.12B | | -12.27% | 1.09B |
Medical & Diagnostic Laboratories
|